Trial Profile

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Pembrolizumab (Primary) ; Tisotumab-vedotin (Primary)
Indications Adenocarcinoma; Colorectal cancer; Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Pancreatic cancer; Pharyngeal neoplasms; Solid tumours; Squamous cell cancer
Focus Therapeutic Use
Acronyms innovaTV 207
Sponsors Seagen

Most Recent Events

13 Jan 2026 Planned End Date changed from 13 Sep 2026 to 31 Mar 2027.
08 Oct 2025 Planned primary completion date changed from 13 Sep 2025 to 13 Jan 2026.
12 Aug 2025 Planned End Date changed from 14 Aug 2026 to 13 Sep 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com